Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans

Blood

Volumn 89, Issue 10, 1997, Pages 3727-3734

  Van Der Poll, Tom ^b   Coyle, Susette M ^b   Levi, Marcel ^b   Jansen, Patty M ^b   Dentener, Mieke ^b   Barbosa, Karen ^b   Buurman, Wim A ^b   Hack, C Erik ^b   Ten Gate, Jan W ^b   Agosti, Jan M ^b   Lowry, Stephen F ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DEGRANULATION; DIMERIZATION; DRUG EFFECT; ENDOTHELIUM CELL; ENDOTOXEMIA; FIBRINOLYSIS; HORMONE RELEASE; HUMAN; IMMUNE RESPONSE; INFLAMMATORY CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; TISSUE INJURY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CYTOKINES; E-SELECTIN; ENDOTOXEMIA; ENDOTOXINS; FIBRINOLYSIS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INJECTIONS, INTRAVENOUS; LEUKOCYTE COUNT; MALE; NEUTROPHILS; PHOSPHOLIPASES A; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17044458176     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Van der Poll T, Lowry SF: Tumor necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense? Shock 3:1, 1995
2. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, Cerami A, Shires GT, Lowry SF: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 166:147, 1988
3. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481, 1988
4. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 76:2520, 1990
5. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD, Shires GT, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 234:470, 1986
6. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662, 1987
7. Hinshaw LB, Tekamp-Olson P, Chang ACK, Lee PA, Taylor FB Jr, Murray CK, Peer GT, Emerson TE Jr, Passey B, Kuo GC: Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Circ Shock 30:279, 1990
8. Van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322:1622, 1990
9. Van der Poll T, Levi M, Büller HR, van Deventer SJH, de Boer JP, Hack CE, ten Cate JW: Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174:729, 1991
10. Van der Poll T, Jansen PM, van Zee KJ, Welborn III MB, de Jong I, Hack CE, Loetscher H, Lesslauer W, Lowry SF, Moldawer LL: Tumor necrosis factor α induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood 88:922, 1996
11. Van der Poll T, Levi M, van Deventer SJH, ten Cate H, Haagmans BL, Biemond BJ, Büller HR, Hack CE, ten Cate JW: Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 83:446, 1994
12. Biemond BJ, Levi M, ten Cate H, van der Poll T, Büller HR, Hack CE, ten Cate JW: Plasminogen activator and PAI-1 release during experimental endotoxemia in chimpanzees: Effects of various interventions in the cytokine and coagulation cascades. Clin Sci 88:587, 1995
13. Van der Poll T, van Deventer SJH, Hack CE, Wolbink GJ, Aarden LA, Büller HR, ten Cate JW: Effects on leukocytes following injection of tumor necrosis factor into healthy humans. Blood 79:693, 1992
14. 2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees. Clin Exp Immunol 100:21, 1995
15. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155:5038, 1995
16. Van der Poll T, Coyle SM, Kumar A, Barbosa K, Agosti J, Lowry SF: Regulation of surface receptors for tumor necrosis factor and interleukin 1 on circulating monocytes and granulocytes during human endotoxemia. Effect of neutralization of endotoxin-induced TNF activity by infusion of a recombinant dimeric TNF receptor. J Immunol 158:1490, 1997
17. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548, 1993
18. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99, 1986
19. Van Zee KJ, Kohno T, Fischer E, Rock SC, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 89:4845, 1992
20. Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G: A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 48:266, 1982
21. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Büller HR, van Deventer SJH, Hack CE, ten Cate JW, Rosenberg RD: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 93:114, 1994
22. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, Ahern TJ, Buurman WA: E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543, 1992
23. Helle M, Boeije L, de Groot ER, de Vos A, Aarden LA: Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: Synovial fluids and sera. J Immunol Methods 138:47, 1991
24. Hack CE, Hart M, Strack van Schijndel RJM, Eerenberg AJM, Nuijens JH, Thijs LG, Aarden LA: Interleukin-8 in sepsis: Relation to shock and inflammatory mediators. Infect Immunol 60:2835, 1992
25. Van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW, van Deventer SJH: Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 180:1985, 1994
26. 1,-antitrypsin and lactoferrin in sepsis: Evidence for neutrophils as mediators of fatal sepsis. J Lab Clin Med 119:159, 1992
27. Froon AH, Denterer MA, Greve JW, Ramsay G, Buurman WA: Lipopolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis 171:1250, 1995
28. Bone RC: The pathogenesis of sepsis. Ann Intern Med 115:457, 1991
29. Nam MH, Reda D, Boujoukos AJ, Agosti J, Suffredini AF: Recombinant human dimeric tumor necrosis factor (TNF) receptor (TNFR:Fc): Safety and pharmacokinetics in human volunteers. Clin Res 41:380A, 1993
30. Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, Cohen J: Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180:2173, 1994
31. Suffredini AF, Harpel PC, Parrillo JE: Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 320:1165, 1989
32. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic proper ties by tumor necrosis factor. J Exp Med 163:740, 1986
33. Scarpati EM, Sadler JE: Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 264:20705, 1989
34. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ: Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263:5797, 1988
35. Hooper WC, Philips DJ, Ribeiro MJA, Benson JM, George VG, Ades EW, Evatt BL: Tumor necrosis factor-α downregulates protein S secretion in human microvascular and umbilical vein endothelial cells but not in the HepG-2 hepatoma cell line. Blood 84:483, 1994
36. Creasey AA, Chang ACK, Feigen L, Wün TC, Taylor FB Jr, Hinshaw LB: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91:2850, 1993
37. Van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJH, Eerenberg AJM, de Groot ER, Jansen J, Gallati H, Büller HR, ten Cate JW, Aarden LA: Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 179:1253, 1994
38. Stouthard JML, Levi M, Hack CE, Veenhof CHN, Romijn JA, Sauerwein HP, van der Poll T: Interleukin 6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 76:738 ,1996
39. Newman W, Beall LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, Gopal TV, Wiener-Kronisch J, Matthay MA: Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 150:644, 1993
40. 2 regulates critical inflammatory mediators of multiple organ failure. J Surg Res 56:199, 1994
41. 2-activating protein in endothelial cells. Biochem J 250:125, 1988
42. Redl H, Schlag G, Schiesser A, Davies J: Tumor necrosis factor is a mediator of phospholipase release during bacteremia in baboons. Am J Physiol 264:H2119, 1993
43. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E, for the Soluble TNF Receptor Sepsis Study Group: Treatment of septic shock with the tumor necrosis factor:Fc fusion protein. N Engl J Med 334:1697, 1996
44. Echtenacher B, Falk W, Mannel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145:3762, 1990
45. Van der Poll T, Keogh CV, Buurman WA, Lowry SF: Passive immunization against tumor necrosis factor α impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 155:603, 1997